Table 3. Examples of PEG alternatives and their immunological properties.
Polymer | Type of response | Mechanism |
---|---|---|
Poly(vinylpyrrolidone) | Anaphylaxis; inhibition of blood coagulation | IgE-mediated activation and degranulation of mast cells’ Prolongation of APTT; inhibition of coagulation factor VIII; |
Poly(sorbate) | HSR; anaphylactoid reactions (CARPA); true anaphylaxis | Complement activation; IgE-mediated mast cell degranulation; basophil activation |
Poly(glycerol) | Allergic contact dermatitis | unknown |
Poly(docanol) | Allergic contact dermatitis, skin sensitization | unknown |
Poly(oxazoline) | Inhibition of blood coagulation | Prolongation of APTT |
Poly(2-methyl-2-oxazoline) (PMOXA) | Pseudoallergy; increased uptake by phagocytes | Complement activation; opsonization; induction of polymer-specific IgM |
Poly(acrylamide) | Contact dermatitis to monomer components | unknown |
Poly(N-acryloyl morpholine) | Skin sensitization by monomers | unknown |
Poly(sialic) acid | Immunogenicity Monomers inhibit complement and phagocytosis Monomers enhance allergy |
Unknown Binding to complement factor H Mast cell degranulation |
Pro, Ala and Ser (PAS) polypeptide | Potential immunogenicity | Tendency to aggregate |
Poly(glutamic acid) | Late onset anaphylaxis Adjuvanticity | Polymer specific IgE DC maturation |
Poly-(carboxybetaine) | Inflammation | Cytokine induction |
Ala, Asp, Gly, Pro, Ser, and Thr polypeptide (XTEN) | Potential immunogenicity | Tendency to aggregate (though at a less degree than PAS) |
Heparin | Inhibition of blood coagulation; immunogenicity; HIT; delayed anaphylaxis | Prolongation of APTT; inhibition of coagulation factors; type II antigen; formation of complex with the chemokine PF4 resulting in an irreversible aggregation and depletion of blood platelets |
Hyaluronic acid | Delayed type hypersensitivity, anaphylaxis and vascular thrombosis | Unknown; in some cases development of these reactions were preceded by viral infections |